Handelsavisen
prelaunch
Companies Healthcare KREB.NS
KR
KREB.NS NSE (India) Pharmaceuticals

Kreb.Ns

$56,10
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-50,1 %
ROE
18,4 %
Net margin
-62,2 %
Debt / equity
-1,45
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

KREB.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products and medical research solutions.

Business. KREB.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products and medical research solutions.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
18,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning KREB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to KREB.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    KREB.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products and medical research solutions.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    KREB.NS exhibits a highly leveraged capital structure, with total liabilities of INR 31.53 billion and total equity of INR -1.46 billion, resulting in a debt-to-equity ratio of -1.45. The company's liquidity position is weak, as indicated by a current ratio of 0.1, suggesting significant short-term liquidity constraints. The negative free cash flow of INR -238.13 million and operating cash flow of INR -78.91 million further highlight the company's inability to generate positive cash from operations.

    Profitability metrics are concerning, with a net loss of INR -269.39 million and an operating loss of INR -217.19 million. The return on equity of 18.42% is misleading due to the negative equity base, while the return on assets of -15.94% indicates poor asset utilization. These figures fall significantly below the industry median for profitability and asset efficiency, suggesting underperformance relative to peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth potential. The absence of segment or geographic breakdown in the financial data further obscures the company's risk profile.

    Growth prospects are limited, with no disclosed revenue growth in the current fiscal year and no forward-looking guidance provided. The company's operating losses and negative cash flows suggest a lack of momentum or strategic investment in growth initiatives. The absence of capital expenditure data beyond INR -35.63 million also indicates minimal reinvestment in long-term capabilities.

    The risk assessment highlights significant liquidity and solvency concerns, with a composite risk score indicating medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a red flag for creditors and investors. No dilution sources are identified in the risk assessment, but the company's negative equity position could necessitate future equity issuance to fund operations.

    Recent filings and transcripts are not available in the provided data, limiting insight into management's strategic direction or operational updates. The absence of recent disclosures may indicate a lack of transparency or a focus on internal restructuring.

    Key takeaways
    • KREB.NS is highly leveraged with a negative equity position and weak liquidity.
    • The company is unprofitable, with significant operating and net losses.
    • Revenue and geographic diversification are not disclosed, increasing concentration risk.
    • Growth prospects are limited, with no forward-looking guidance or capital reinvestment.
    • Liquidity and solvency risks are elevated, with no immediate dilution pressure identified.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $56,10
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    -$1.46B
    Net cash
    -$2.12B
    Current ratio
    0.1
    Debt / equity
    -1.4
    ROA
    -15.9%
    ROE
    18.4%
    Cash conversion
    29.0%
    CapEx / revenue
    -8.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-50,1 %Bottom quartile
    Net Margin-62,2 %Bottom quartile
    ROE18,4 %Above P75
    Capex / Rev-8,2 %Below median
    D/E-1,45Best in class
    Cash Conv0,29Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • KREB.NS Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    KREB.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage